RESEARCH USE ONLY: All products are for laboratory research purposes only. Not for human or animal consumption.
By using this site, you confirm you are 21+ and acknowledge these products are not FDA approved.
← Back to Research Library
Mechanism of Action
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist. The GIP component enhances beta-cell insulin secretion and promotes fat oxidation, while GLP-1 activation provides appetite suppression and glucose regulation. Exhibits biased agonism at both receptors for synergistic effects.
Key Research Findings
- SURMOUNT-1: 22.5% mean weight loss at 15mg dose, 36.4% achieving >=25% weight loss
- SURPASS-2: Superior to semaglutide 1mg for both HbA1c reduction and weight loss
- SURPASS-4: Superior glycemic control vs insulin glargine with weight loss vs gain
- Demonstrated improvements in blood pressure, lipids, and inflammatory markers
Peer-Reviewed Studies (4)
Jastreboff AM, Aronne LJ, et al.
New England Journal of Medicine (2022)
Tirzepatide produced up to 22.5% weight reduction at 72 weeks (SURMOUNT-1)
Frias JP, Davies MJ, et al.
New England Journal of Medicine (2021)
Tirzepatide superior to semaglutide 1mg for HbA1c and weight loss (SURPASS-2)
Del Prato S, Kahn SE, et al.
Lancet (2021)
Superior glycemic control vs insulin glargine with weight loss (SURPASS-4)
Willard FS, Douros JD, et al.
JCI Insight (2020)
Characterized biased agonism at both receptors explaining distinct pharmacological profile
Research Disclaimer: The studies referenced above are from publicly available peer-reviewed literature. Pepta Labs products are sold strictly for research purposes. They are not intended for human consumption, therapeutic use, or as dietary supplements. All information is provided for educational and research reference only.